- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tarrytown Today
By the People, for the People
OFI Invest Asset Management Buys Regeneron Pharmaceuticals Shares
Institutional investor adds 31,265 shares of biotech firm to portfolio
Apr. 9, 2026 at 11:18am
Got story updates? Submit your updates here. ›
A major institutional investment in Regeneron Pharmaceuticals highlights the complex financial machinery powering the biotech industry.Tarrytown TodayOFI Invest Asset Management acquired a new stake of 31,265 shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company's latest 13F filing with the SEC. The shares were valued at approximately $24.1 million.
Why it matters
Regeneron is a prominent biopharmaceutical company known for its innovative drug discovery technologies and pipeline of therapies for serious medical conditions. This investment by a major institutional investor signals confidence in the company's long-term growth potential.
The details
OFI Invest Asset Management, a global investment management firm, added the Regeneron shares to its portfolio in Q4 2025. The purchase represents a new stake for the firm, which previously did not hold any Regeneron stock. The 31,265 shares acquired are valued at around $24.1 million based on Regeneron's stock price at the end of the quarter.
- OFI Invest Asset Management acquired the Regeneron shares in the fourth quarter of 2025.
- Regeneron's stock price closed at $775.53 on Thursday, April 9, 2026.
The players
OFI Invest Asset Management
A global investment management firm that acquired a new stake in Regeneron Pharmaceuticals in Q4 2025.
Regeneron Pharmaceuticals, Inc.
A U.S.-based biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious medical conditions.
The takeaway
This investment by a major institutional investor underscores the confidence in Regeneron's long-term growth potential as a leader in the biopharmaceutical industry. The company's innovative drug discovery capabilities and pipeline of therapies continue to attract interest from the investment community.
